RHAMM-target peptides inhibit invasion of breast cancer cells

Akentieva, Natalia

doi:10.24190/ISSN2564-615X/2017/02.05

Abstract

RHAMM is hyaluronan- receptor with multiple functions in the cell, RHAMM is involved in proliferation, motility, migration, invasion, mitotic spindle formation in tumour cells. Therefore, RHAMM could be a relevant target for molecular targeted therapies against tumors.The role of RHAMM-target peptides in inhibition invasion for preventing breast cancer has not yet been investigated. Base on this, we analyzed the RHAMM-target peptides for their therapeutic activity against breast cancer cells. In the present study, we examined the effect of RHAMM-target peptides on the invasion of breast cancer cells (MDAMB- 231), using confocal microscopy. We shown that RHAMM-target peptides decreased formation of invadopodia of breast cancer cells. The treatment of breast cancer cells by RHAMM -target peptides inhibited the invasion up to 99 %. Additionally, RHAMM-target peptides induced the morphological changes of of breast cancer cells. Therefore, based on these results, we can conclude that RHAMM-target peptides may be potential anti-cancer agents.

References

1. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.2.
Search in Google Scholar Back to article
2. Siu, Albert L. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2016, 164: 279-96.10.7326/M15-288626757170
Search in Google Scholar Back to article
3. Kakde D., Jain D., Shrivastava V., Kakde R. and Patil A.T. Cancer therapeutics-opportunities, challenges and advances in drug delivery. Journal of Applied Pharmaceutical Science. 2011, 1 (9): 1-10.
Search in Google Scholar Back to article
4. Zheleva D. I., Fischer P.M., Zhelev N. Z., Melville J. E., Gavine A-L., and Lane D. P. Design of cell-permeable peptides inhibitors of cyclin D1/ CDK4 complex. M. Nature Biotech. Sh.R.2000, 11: 25-30.
Search in Google Scholar Back to article
5. Eldar-Finkelman H. and Eisenstein M. Peptide inhibitors targeting protein kinases. Current Pharmaceutical Design. 2009, 15 (21): 2463-2470.10.2174/13816120978868225319601843
Search in Google Scholar Back to article
6. Rosca E.V., Koskimaki J.E., Rivera C.G., Pandey N.B., Tamiz A.P. and Popel A.S. Antiangiogenic peptides for cancer therapeutics. Current Pharmaceutical Biotechnology.2011, 12 (8): 1101-1116.10.2174/138920111796117300311425621470139
Search in Google Scholar Back to article
7. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., MacKenzie M., Melville J., Stewart K., Wang S., Zhelev N., Zheleva D., Lane D.P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002, 102 (5):463-470.10.1002/ijc.1073812432547
Search in Google Scholar Back to article
8. Mochly-Rosen D. and Qvit N. Peptide inhibitors of protein-protein interactions: from rational design to the clinic. Chimica Oggi. 2010, 28 (1): 14-16.
Search in Google Scholar Back to article
9. Smolarczyk R., Cichon T., Graja K., Hucz J., Sochanik A., and Szala S. Antitumor effect of RGD- 4C-GG-D (KLAKLAK) 2 peptide in mouse B16(F10) melanoma model. Acta Biochimica Polonica. 2006, 53 (4): 801-805.10.18388/abp.2006_3309
Search in Google Scholar Back to article
10. Liang J.F. and Yang V.C. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg. Med. Chem. Lett. 2005.15: 5071-5075.10.1016/j.bmcl.2005.07.08716168650
Search in Google Scholar Back to article
11. Akenteva N.P, Shushanov S.S, Kotelnikov A.I. Effects of RHAMM/ HMMR-Selective Peptides on Survival of Breast Cancer Cells. Bulletin of Experimental Biology and Medicine (Russia). 2015, 159 (5): 618-621.
Search in Google Scholar Back to article
12. Luyt L.G., Turley E.A., Esguerra K.V. Rhamm binding peptides. International Patent WO2011/150495. London Health Sciences Centre Research Inc. 2011.
Search in Google Scholar Back to article
13. Esguerra K.V., Tolg C., Akentieva N., Price M., Cho C.F., Lewis J.D., McCarthy J.B., Turley E.A., Luyt L.G. Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR). Integr. Biol. (Camb).2015, 7 (12): 1547-1560.
Search in Google Scholar Back to article
14. Akentieva N.P., Shushanov S.S. RHAMM (receptor hyaluronan-mediated motility)-target peptides induce apoptosis in prostate cancer cells. Problems in oncology. 2016, 62 (3):512-518.
Search in Google Scholar Back to article
15. Aina O.H., Sroka T.C., Chen M.L. and Lam K.S. Therapeutic cancer targeting peptides. Biopolymers. 2002, 66 (3): 184-199.10.1002/bip.1025712385037
Open DOI Search in Google Scholar Back to article
16. Zhasloff, M. Antimicrobial peptides of multicellular organisms. Nature. 2002, 415: 389-395.10.1038/415389a11807545
Search in Google Scholar Back to article
17. Brogden K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev.Microbiol. 2005, 3: 238-250.10.1038/nrmicro109815703760
Open DOI Search in Google Scholar Back to article
18. Mader J.S., Hoskin, D.W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin. Investig. Drugs. 2006, 15: 933-946.10.1517/13543784.15.8.93316859395
Search in Google Scholar Back to article
19. Kim Y.J., Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj.J. 1997, 14: 569-576.10.1023/A:1018580324971
Search in Google Scholar Back to article
20. Lindgren M., Rosenthal-Aizman K., Saar, K., Eiriksdottir, E., Jiang, Y., Sassian, M., Ostlund, P., Hallbrink, M., and Langel, U. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem. Pharmacol. 2006, 71: 416-425.10.1016/j.bcp.2005.10.048
Search in Google Scholar Back to article
21. Liang, J.F., and Yang, V.C. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg. Med. Chem. Lett. 2005, 15: 5071-5075.10.1016/j.bmcl.2005.07.087
Open DOI Search in Google Scholar Back to article
22. Steiner H, Hultmark D., Engstrom A, Bennich H, Boman HG. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature. 1981; 292 (5820):246-248.10.1038/292246a0
Search in Google Scholar Back to article
23. Lehrer RI. Primate defensins. Nat. Rev. Microbiol. 2004, 2 (9): 727-738.
Search in Google Scholar Back to article
24. Hancock REW. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 2001, 1 (3):156-164.10.1016/S1473-3099(01)00092-5
Search in Google Scholar Back to article
25. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs. 2003, 63 (4):389-406.10.2165/00003495-200363040-0000512558461
Search in Google Scholar Back to article
26. Otvos L. Jr. Antibacterail paptides and proteins with multiple cellular targets. J. Pept. Sci. 2005, 11 (11): 697-706.10.1002/psc.69816059966
Open DOI Search in Google Scholar Back to article
27. Powers J-PS., Hanckock REW. The relationship between peptide structure and antibacterial activity. Peptides 2003, 24 (11):1681-1691.10.1016/j.peptides.2003.08.02315019199
Search in Google Scholar Back to article
28. Nicolaou KC, Murphy F., Barluenga S., Ohshima T., Wei H, Xu J., Gray DLF, Baudoin O. Total synthesis of the novel immunosuppressant sanglifehrin A, J.Am.Chem.Soc. 2000, 122: 3830-3838.10.1021/ja994285v
Search in Google Scholar Back to article
29. White J.D., Hong J., Robarge LA. Total synthesis of cryptophycins- 1, -3, -4 and -24 (arenastatin A0 and -29, cytotoxic depsipeptides from cyanobacteria of the nostocacae. J. Org. Chem. 1999, 64: 6206-6216.10.1021/jo9907585
Search in Google Scholar Back to article
30. Xia Z., Smith CD. Total synthesis of dendroamide A, a novel cyclic peptide that reverses multiple drug resistance. J. Org. Chem. 2001, 66:3459-3466.10.1021/jo005783l11348130
Search in Google Scholar Back to article
31. Boger DL, Zhou J., Borzilleri RM., Nukii S., Castle SL. Synthesis of (9R, 12 S)- and (9S, 12 S)-cycloisodityrosine and their N-methyl derivatives. J. Org. Chem. 1997, 62:2054-2069.10.1021/jo961346o11671510
Open DOI Search in Google Scholar Back to article
32. Inoue T., Inaba T., Umezawa I., Yuasa M., Itokawa H., Ogura K., Komatsu K, Hara H, Hoshino O. Reglose-lective synthesis of 14-membered blaryl ethers. Total synthesis of RA V11 and deoxybouvardin. Chem. Pharm. Bull. 1995, 43: 1325-1335.10.1248/cpb.43.1325
Open DOI Search in Google Scholar Back to article
33. Davies J.S. REW. The cyclization of peptides and depsipeptides. J. Peptide Sci. 2003, 9:471-501.10.1002/psc.49112952390
Search in Google Scholar Back to article
34. Vives, E., Schmidt, J., and Pelegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta. 2008, 1786: 126-38.10.1016/j.bbcan.2008.03.00118440319
Search in Google Scholar Back to article
35. Myrberg, H., Zhang, L., Mae, M., and Langel, U. Design of a tumor- homing cell-penetrating peptide. Bioconjug.Chem. 2008, 19: 70-75.10.1021/bc070113918001077
Search in Google Scholar Back to article
36. Jiang, T., Olson, E.S., Nguyen, Q.T., Roy, M., Jennings, P.A., and Tsien, R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA. 2004, 101:17867-72.10.1073/pnas.040819110153931415601762
Search in Google Scholar Back to article
37. Pipkorn, R., Waldeck, W., Spring, H., Jenne, J.W., and Braun, K. Delivery of substances and their target-specific topical activation. Biochim. Biophys. Acta. 2006, 1758: 606-10.10.1016/j.bbamem.2006.03.03616730647
Search in Google Scholar Back to article
38. Telmer, P. G.; Tolg, C.; McCarthy, J. B.; and Turley, E. A. How does protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression? Commun. Integr. Biol. 2011, 4(2): 182-185.
Search in Google Scholar Back to article
39. Laurent, T. C., and Fraser, J. R. E. Hyaluronan. FASEB J. 1992, 6: 2397-2404.10.1096/fasebj.6.7.1563592
Search in Google Scholar Back to article
40. Laurent, T. C. Biochemistry of Hyaluronan. Acta Otolaryngol Suppl. 1987, 442: 7-24.10.3109/000164887091028333124495
Search in Google Scholar Back to article
41. Lee, J. Y.; and Spicer, A. P. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol. 2000, 12(5): 581-586.10.1016/S0955-0674(00)00135-6
Open DOI Search in Google Scholar Back to article
42. Tzircotis G, Thorne RF, Isacke CM. Chemotaxis towards hyaluronan is dependent on CD44 expression and modulated by cell type variation in CD44-hyaluronan binding. J Cell Sci. 2005, 118:5119-5128.10.1242/jcs.02629
Open DOI Search in Google Scholar Back to article
43. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res. 2005, 310:205-217.10.1016/j.yexcr.2005.07.026
Search in Google Scholar Back to article
44. Bourguignon LY, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J. Biol. Chem. 2002, 277:39703-39712.10.1074/jbc.M204320200
Search in Google Scholar Back to article
45. Naot, D., Sionov, R.V., and Ish-Shalom, D. CD44: Structure, function, and association with the malignant process. Adv. Cancer Res.1997, 71: 241-319.10.1016/S0065-230X(08)60101-3
Search in Google Scholar Back to article
46. Turley E.A., Noble P.W., Bourguignon L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 2002, 277: 4589-4592.10.1074/jbc.R100038200
Search in Google Scholar Back to article
47. Adamia S., Maxwell C.A., Pilarski L.M. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2005, 5: 3-1410.2174/1568006053005056
Search in Google Scholar Back to article
48. Hardwick C., Hoare K., Owens R., Hohn H.P., Hook M., Moore D., Cripps V., Austen L., Nance D.M., Turley E.A. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J. Cell. Biol. 1992, 117:1343-1350.10.1083/jcb.117.6.1343
Search in Google Scholar Back to article
49. Hall C.L., Yang B., Yang X., Zhang S., Turley M., Samuel S., Lange L.A., Wang C., Curpen G.D., Savani R.C., Greenberg A.H., Turley E.A. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell. 1995, 82:19-26.10.1016/0092-8674(95)90048-9
Search in Google Scholar Back to article
50. Maxwell C.A., Keats J.J., Crainie M., Sun X., Yen T., Shibuya E., Hendzel M., Chan G., Pilarski L.M. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol. Biol. Cell. 2003,14:2262-2276.10.1091/mbc.E02-07-037719487612808028
Open DOI Search in Google Scholar Back to article
51. Assmann V., Jenkinson D., Marshall J.F., Hart I.R. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubule and actin filaments. J. Cell. Sci. 1999, 112 (Pt 22):3943-3954.10.1242/jcs.112.22.3943
Search in Google Scholar Back to article
52. Joukov V., Groen A.C., Prokhorova T., Gerson R., White E., Rodriguez A., Walter J.C., Livingston D.M. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell. 2006, 127:539-552.10.1016/j.cell.2006.08.053
Search in Google Scholar Back to article
53. Gust K. M., Hofer M. D., Perner S.R., Chinnaiyan A. M., VaramballyS., Moller P., Rinnab L., Rubin M. A., Greiner J., Schmitt M., Kuefer R., and Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia. 2009, 11(9): 956-963.10.1593/neo.09694
Open DOI Search in Google Scholar Back to article
54. Wang C., Thor A.D., Moore D.H., Zhao Y., Kerschmann R., Stern R., Watson P.H., and Turley E. A. The overexpression of RHAMM, a hyaluronan- binding protein that regulates ras signalling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer rogression. Clin. Cancer Res.1998, 4(3): 567-576.
Search in Google Scholar Back to article
55. Greiner J., Ringhoffer M., Taniguchi M., Schmitt A., Kirchner D., Krahn G., Heilmann V., Gschwend J., Bergmann L., Dohner H., and Schmitt M. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chromic myeloid leukemia. Exp. Hematol. 2002, 30(9): 1029-1035.10.1016/S0301-472X(02)00874-3
Open DOI Search in Google Scholar Back to article
56. Assmann V., Marshall J. F., Fieber C., Hofmann M., and Hart I.R. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer. J. Cell Sci. 1998, 111: 1685-1694.10.1242/jcs.111.12.16859601098
Search in Google Scholar Back to article
57. Maxwell C. A., Rasmussen E., Zhan F., Keats J. J., Adarnia S., Strachan E., Crainie M., Walker R., Belch A. R., Pilarski L. M., Barlogie B., Shaughnessy J. Jr., and Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004, 104(4): 1151-1158.10.1182/blood-2003-11-407915105292
Search in Google Scholar Back to article
58. Crainie M., Belch A. R., Mant M. J., and Pilarski L. M. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood. 1999, 93(5): 1684-1696.10.1182/blood.V93.5.1684
Search in Google Scholar Back to article
59. Wang C., Thor A. D., Moore D. H., Zhao Y., Kerschmann R., Stern R., Watson P. H., Turley E. A. The overexpression of RHAMM, a hyaluronan binding protein that regulates ras signalling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer P Progression. Clin. Cancer Res. 1998, 4(3): 567-576.
Search in Google Scholar Back to article
60. Assman V., Gillett C. E., Poulsom R., Ryder K., Hart I. R., and Hanby A. M. The pattern of expression of the microtubule-binding protein RHAMM/IHAMP im mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J. Pathol. 2001, 195(2): 191-196.
Search in Google Scholar Back to article
61. Tolg C., Hamilton S. J., Morningstar L., Zhang J., Esguerra K. V., Telmer P. G., Luyt L. G., Harrison R., McCarthy J. B., Turley E. A. RHAMM promotes interphase microtubule instability and mitotic spindle integrity trough MEK1/ERK1, 2 activity. J Biol. Chem., 2010, 285: 26461-26474.10.1074/jbc.M110.121491292407920558733
Search in Google Scholar Back to article
62. Kurokawa H., Kazuto N., Fukumoto H., Tomonari A., Suzuki T., Saijo N. Alteration of caspase-3 (CPP32/Yama/apopaim) in wild-type MCF-7 breast cancer cells. Oncology Rep.1999, 6: 33-37.10.3892/or.6.1.339864397
Search in Google Scholar Back to article
63. Rizzardi A.E., Vogel R.I., Koopmeiners J.S., Forster C.L., Marston L.O., Rosener N.K., Akentieva N., Price M.A., Metzger G.J., Warlick C.A., Henriksen J.C., Turley E.A., McCarthy J.B., Schmechel S.C. 2014. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer. 120 (12), 1800-1809.
Search in Google Scholar Back to article
64. Sliva D., Rizzo M.T., English D. Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J. Biol. Chem. 2002, 277:3150-7.10.1074/jbc.M10957920011689575
Search in Google Scholar Back to article
65. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999, 96:857-68.10.1016/S0092-8674(00)80595-4
Open DOI Search in Google Scholar Back to article
66. Byeong-Chel Lee, Tae-Hee Lee, Shalom Avraham and Hava Karsenty Avraham. Involvement of the Chemokine Receptor CXCR4 and Its Ligand Stromal Cell-Derived Factor 1α in Breast Cancer Cell Migration Through Human Brain Microvascular Endothelial Cells. Mol. Cancer. Res. 2004, 2: 327-337.10.1158/1541-7786.327.2.6
Search in Google Scholar Back to article
67. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410:50-6.10.1038/35065016
Search in Google Scholar Back to article
68. Soule H.D., Vazguez J., Long, A., Albert S. and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 1973, 51:1409-1416.10.1093/jnci/51.5.1409
Open DOI Search in Google Scholar Back to article
69. Levenson A.S., Jordan V.C. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 1997, 57: 3071-3078.
Search in Google Scholar Back to article
70. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum-based anti-cancer chemotherapy. Cancer Treat. Rev. 1998, 24: 331-344.10.1016/S0305-7372(98)90056-1
Open DOI Search in Google Scholar Back to article
71. Maxwell C.A., McCarthy J., Turley E. Cell-surface and mitotic-spindle Rhamm: moonlighting or dual oncogenic functions? J. Cell. Sci. 2008, 121: 925-932.10.1242/jcs.02203818354082
Search in Google Scholar Back to article
72. Hus I., Kawiak J., Tabarkiewicz J., Radej S., Hoser G., Bojarska-Junak A., Schmitt M., Giannopoulos K., Dmoszynska A., Rolinski J. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. Oncol Rep. 2008, 20(2):443-51.
Search in Google Scholar Back to article
73. Zlobec I., Terraciano L., Tornullo L., Gunhert U., Vuong T., Jass J.R., Lugli A. Role of Rhamm within the hierarchy of well-established prognostic factors in colorectal cancer. Gur. 2008.10.1136/gut.2007.14119218436576
Search in Google Scholar Back to article
74. Yamano Y., Uzawa K., Shinozuka K., Fushimi K., Ishigami T., Nomura H., Ogawara K., Shiiba M., Yokoe H., Tanzawa H. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma. Int. J. Oncol. 2008, 32: 10001-9.10.3892/ijo.32.5.1001
Search in Google Scholar Back to article
75. Tolg C., Poon R., Fodde R., Turley E.A., Alman B.A. Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoids tumor). Oncogene. 2003, 22: 6873-82.10.1038/sj.onc.120681114534534
Open DOI Search in Google Scholar Back to article
76. Rein D.T., Roehrig K., Schondorf T., Lazar A., Fleisch M., Niederacher D., Bender H.G., Dall P. Expression of the hyaluronan receptor Rhamm in endometrial carcinoma suggests a role in tumor progression and metastasis. J. Cancer Res. Clin. Oncol. 2003, 129: 161-4.10.1007/s00432-003-0415-012712331
Search in Google Scholar Back to article
77. Sohr S. and Engeland K. Rhamm is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle. 2008, 7 (21): 3448-3460.10.4161/cc.7.21.701418971636
Search in Google Scholar Back to article
78. Lippman M.E. and Bolan G. Oestrogen-responsive human breast cancer in long-term tissue culture. Nature. 1975, 256:592-593.10.1038/256592a0170527
Search in Google Scholar Back to article
79. Seals D.F. et al. The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell. 2005, 7:155-165.10.1016/j.ccr.2005.01.00615710328
Open DOI Search in Google Scholar Back to article
80. Yamaguchi H. et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J. Cell. Biol. 2005, 168: 441-452.10.1083/jcb.200407076217173115684033
Search in Google Scholar Back to article
81. Weaver A.M. Invadopodia : specialized cell structures for cancer invasion. Clin. Exp. Metastasis. 2006, 23: 97-105.10.1007/s10585-006-9014-116830222
Search in Google Scholar Back to article
82. Diaz B. et al. Tks5-dependent, Nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal. 2009, 2:ra53.10.1126/scisignal.2000368281064019755709
Search in Google Scholar Back to article
83. Clark E.S. and Weaver A.M. A new role for cortactin in invadopodia: regulation of protease secretion. Eur. J. Cell Biol. 2008, 87:581-590.10.1016/j.ejcb.2008.01.008256693318342393
Search in Google Scholar Back to article

RHAMM-target peptides inhibit invasion of breast cancer cells

Abstract

Paradigm

My account